Overview

Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.

Status:
Not yet recruiting

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Lifefactors Zona Franca, SAS

Treatments:

Antibodies
Immunoglobulins
Immunoglobulins, Intravenous